Back to search results

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Abroad (travel likely)RecruitingPHASE3

Conditions

Schizophrenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Neurocrine Clinical Site, Bryant, Arkansas, United States

  • Neurocrine Clinical Site, Little Rock, Arkansas, United States

  • Neurocrine Clinical Site, Anaheim, California, United States

  • Neurocrine Clinical Site, Pico Rivera, California, United States

  • Neurocrine Clinical Site, San Diego, California, United States

  • Neurocrine Clinical Site, Sherman Oaks, California, United States

  • Neurocrine Clinical Site, Torrance, California, United States

  • Neurocrine Clinical Site, Hollywood, Florida, United States

  • Neurocrine Clinical Site, Miami Lakes, Florida, United States

  • Neurocrine Clinical Site, Atlanta, Georgia, United States

  • Neurocrine Clinical Site, Decatur, Georgia, United States

  • Neurocrine Clinical Site, Snellville, Georgia, United States

  • Neurocrine Clinical Site, Chicago, Illinois, United States

  • Neurocrine Clinical Site, Gaithersburg, Maryland, United States

  • Neurocrine Clinical Site, Watertown, Massachusetts, United States

  • Neurocrine Clinical Site, Marlton, New Jersey, United States

  • Neurocrine Clinical Site, Staten Island, New York, United States

  • Neurocrine Clinical Site, The Bronx, New York, United States

  • Neurocrine Clinical Site, Austin, Texas, United States

  • Neurocrine Clinical Site, DeSoto, Texas, United States

  • Neurocrine Clinical Site, Houston, Texas, United States

Study leads

  • Clinical Development Lead

    Study Director

    Neurocrine Biosciences

View source on ClinicalTrials.gov(opens in a new tab)